Today: 7 February 2026
Subscribe

Singtel stock price today: Shares flat near S$4.56 as MAS holds policy, AI theme lingers

Singtel stock price today: Shares flat near S$4.56 as MAS holds policy, AI theme lingers

Singtel shares closed unchanged at S$4.56 Thursday as 6.2 million shares traded, following a 0.65% drop in the previous session. The Monetary Authority of Singapore kept policy steady but raised its 2026 inflation forecast. Investors are watching AI infrastructure trends and currency moves ahead of Singtel’s results on Feb. 18. No company-specific news drove today’s trading.
29 January 2026
··
Sembcorp share price jumps as Micron power deal expands and Vietnam park gets green light

Sembcorp share price jumps as Micron power deal expands and Vietnam park gets green light

Sembcorp Industries shares rose 3.4% to S$6.12 Thursday after announcing an expanded 18-year power deal with Micron and approval for a 467-hectare Vietnam industrial park. The company said the Micron contract will not significantly impact FY2026 earnings. Shareholders vote on the proposed Alinta Energy acquisition Jan. 30. FY2025 results are due Feb. 25.
29 January 2026
···
OCBC stock price inches up as Citi-backed securities-lending launch keeps focus on Feb earnings

OCBC stock price inches up as Citi-backed securities-lending launch keeps focus on Feb earnings

OCBC shares rose 0.23% to S$21.34 in Singapore trading Thursday, with about 1.8 million shares changing hands. The bank launched a securities-lending program via Citi, aiming to expand to more clients by 2026. RHB raised its target price for OCBC to S$21.30, expecting single-digit earnings growth and a 60% dividend payout. OCBC will report full-year 2025 results on Feb. 25.
29 January 2026
··
Yangzijiang Shipbuilding share price rises after Evergreen order report; what investors watch next

Yangzijiang Shipbuilding share price rises after Evergreen order report; what investors watch next

Yangzijiang Shipbuilding shares rose 0.9% to S$3.38 in Singapore after reports linked the company to new container-ship orders from Evergreen Marine. Evergreen’s Singapore unit agreed to buy seven 5,900-TEU ships from Yangzijiang’s yard, each priced up to $82 million, as part of a $1.47 billion order program. Trading volume reached 13.6 million shares by 2:47 p.m.
29 January 2026
·
Gold price above $5,500 and silver near $120 — what’s behind the record rush

Gold price above $5,500 and silver near $120 — what’s behind the record rush

Gold hit a record $5,591.61 an ounce Thursday, with silver reaching $119.34, as investors sought safety amid geopolitical and economic tensions. Banks raised price forecasts but warned of risks of sharp reversals. President Trump announced new tariffs on South Korean imports, and the U.S. faces a funding deadline. The Federal Reserve held rates steady, citing persistent inflation above target.
29 January 2026
····
Santos share price edges up on Queensland gas permits as Barossa LNG milestone sets up February results

Santos share price edges up on Queensland gas permits as Barossa LNG milestone sets up February results

Santos closed up 0.29% at A$6.84 after Queensland granted new gas exploration permits to Santos and Drillsearch in the Cooper-Eromanga Basin. The state aims to boost domestic supply as federal rules tighten export quotas from 2027. Santos recently shipped its first Barossa LNG cargo to Japan. Investors await full-year results on Feb. 18.
29 January 2026
···
1 … 265 266 267 268 269 … 2,714

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop